Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients: A critical review

Camillo Porta, Cezary Szczylik, Bernard Escudier

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

The introduction of novel anti-angiogenic therapies has greatly improved the outcome of patients with metastatic renal cell carcinoma (mRCC). The use of these therapies in combination or sequentially is proposed to provide greater efficacy.We have reviewed completed and ongoing clinical trials in mRCC that have reported efficacy and/or safety data of novel therapies used in combination or sequentially.Bevacizumab appears to be a useful partner when combined with interferon (IFN), while controversial results have been reported when combined with temsirolimus and everolimus. Other combinations appear to have unacceptable tolerability or require dose or schedule optimization. Sequencing data provide a clear indication that multiple lines of treatment may extend survival. The 'ideal' sequence, however, is still unknown.In conclusion, novel therapies used in combination or sequentially have potential to provide optimised treatment and patient outcomes in mRCC. The results from ongoing/planned trials are expected to help shape future therapy.

Original languageEnglish
Pages (from-to)323-337
Number of pages15
JournalCritical Reviews in Oncology/Hematology
Volume82
Issue number3
DOIs
Publication statusPublished - Jun 2012

Fingerprint

Renal Cell Carcinoma
Therapeutics
Interferons
Appointments and Schedules
Clinical Trials
Safety
Survival

Keywords

  • Angiogenesis inhibitors
  • Combination
  • Cytokines
  • Renal cell carcinoma
  • Sequencing

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Cite this

Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients : A critical review. / Porta, Camillo; Szczylik, Cezary; Escudier, Bernard.

In: Critical Reviews in Oncology/Hematology, Vol. 82, No. 3, 06.2012, p. 323-337.

Research output: Contribution to journalArticle

@article{30cde6c8a36d4c81b42879f177b7206f,
title = "Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients: A critical review",
abstract = "The introduction of novel anti-angiogenic therapies has greatly improved the outcome of patients with metastatic renal cell carcinoma (mRCC). The use of these therapies in combination or sequentially is proposed to provide greater efficacy.We have reviewed completed and ongoing clinical trials in mRCC that have reported efficacy and/or safety data of novel therapies used in combination or sequentially.Bevacizumab appears to be a useful partner when combined with interferon (IFN), while controversial results have been reported when combined with temsirolimus and everolimus. Other combinations appear to have unacceptable tolerability or require dose or schedule optimization. Sequencing data provide a clear indication that multiple lines of treatment may extend survival. The 'ideal' sequence, however, is still unknown.In conclusion, novel therapies used in combination or sequentially have potential to provide optimised treatment and patient outcomes in mRCC. The results from ongoing/planned trials are expected to help shape future therapy.",
keywords = "Angiogenesis inhibitors, Combination, Cytokines, Renal cell carcinoma, Sequencing",
author = "Camillo Porta and Cezary Szczylik and Bernard Escudier",
year = "2012",
month = "6",
doi = "10.1016/j.critrevonc.2011.06.001",
language = "English",
volume = "82",
pages = "323--337",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients

T2 - A critical review

AU - Porta, Camillo

AU - Szczylik, Cezary

AU - Escudier, Bernard

PY - 2012/6

Y1 - 2012/6

N2 - The introduction of novel anti-angiogenic therapies has greatly improved the outcome of patients with metastatic renal cell carcinoma (mRCC). The use of these therapies in combination or sequentially is proposed to provide greater efficacy.We have reviewed completed and ongoing clinical trials in mRCC that have reported efficacy and/or safety data of novel therapies used in combination or sequentially.Bevacizumab appears to be a useful partner when combined with interferon (IFN), while controversial results have been reported when combined with temsirolimus and everolimus. Other combinations appear to have unacceptable tolerability or require dose or schedule optimization. Sequencing data provide a clear indication that multiple lines of treatment may extend survival. The 'ideal' sequence, however, is still unknown.In conclusion, novel therapies used in combination or sequentially have potential to provide optimised treatment and patient outcomes in mRCC. The results from ongoing/planned trials are expected to help shape future therapy.

AB - The introduction of novel anti-angiogenic therapies has greatly improved the outcome of patients with metastatic renal cell carcinoma (mRCC). The use of these therapies in combination or sequentially is proposed to provide greater efficacy.We have reviewed completed and ongoing clinical trials in mRCC that have reported efficacy and/or safety data of novel therapies used in combination or sequentially.Bevacizumab appears to be a useful partner when combined with interferon (IFN), while controversial results have been reported when combined with temsirolimus and everolimus. Other combinations appear to have unacceptable tolerability or require dose or schedule optimization. Sequencing data provide a clear indication that multiple lines of treatment may extend survival. The 'ideal' sequence, however, is still unknown.In conclusion, novel therapies used in combination or sequentially have potential to provide optimised treatment and patient outcomes in mRCC. The results from ongoing/planned trials are expected to help shape future therapy.

KW - Angiogenesis inhibitors

KW - Combination

KW - Cytokines

KW - Renal cell carcinoma

KW - Sequencing

UR - http://www.scopus.com/inward/record.url?scp=84856877365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856877365&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2011.06.001

DO - 10.1016/j.critrevonc.2011.06.001

M3 - Article

C2 - 21733715

AN - SCOPUS:84856877365

VL - 82

SP - 323

EP - 337

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 3

ER -